LLY vs LMAT: fair value comparison
Eli Lilly and Company and LeMaitre Vascular, Inc. · Updated 2026-10-19
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, LLY currently sits closer to the top of our ranking by discount to fair value. LMAT carries the stronger quality grade.
| LLY | LMAT | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $1,179.27 | $80.82 |
| 12-month range | $813.53–$1,280.34 | $78.80–$117.39 |
| Rank by discount to fair value | #9 of 108 Healthcare | #14 of 108 Healthcare |
| Quality grade | B | A |
| Momentum grade | B | — |
| Leverage | High | Low |
| Margin trend | Expanding | Expanding |
| Revenue growth | High | Strong |
| RSI zone | Overbought | Neutral |
| 50/200-day trend | — | Downtrend |
| DCF cross-check | — | Overvalued |
| 52-week position | The top quarter | The bottom quarter |
Full single-stock breakdowns: LLY fair value analysis · LMAT fair value analysis